BridgeMD
New treatment option for Postoperative Chronic Pain
Official title Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy
ClinicalTrials.gov ID: NCT06778460
What this study is testing
What is Esketamine-lidocaine group?
Esketamine-lidocaine group is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for postoperative chronic pain.
Also referred to as Trial group.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a further observation and follow-up of the patients enrolled in the registration number ChiCTR230007164430 to further evaluate the effect of long-term infusion of esketamine and lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing hepatectomy.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Aged 18-75 years;
- Scheduled for elective hepatectomy;
- ASA grade I-III.
You likely can't join if
- Patients who have been intubated in the ICU following surgery and do not have a planned extubation within 6 hours postoperatively.
- Patients with a body weight less than 40 kg or greater than 100 kg.
- Patients with cardiac conduction system abnormalities (second- or third-degree atrioventricular block) or cardiac insufficiency (left ventricular...
- Patients with severe hepatic insufficiency (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or bilirubin levels more than 2.5 times...
- Patients with a known hypersensitivity to the investigational drug.
- Patients with a history of long-term opioid abuse.
See the full eligibility criteria
- Aged 18-75 years;
- Scheduled for elective hepatectomy;
- ASA grade I-III.
- Patients who have been intubated in the ICU following surgery and do not have a planned extubation within 6 hours postoperatively.
- Patients with a body weight less than 40 kg or greater than 100 kg.
- Patients with cardiac conduction system abnormalities (second- or third-degree atrioventricular block) or cardiac insufficiency (left ventricular ejection fraction \< 50%).
- Patients with severe hepatic insufficiency (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or bilirubin levels more than 2.5 times the upper limit of normal) or renal insufficiency (creatinine...
- Patients with a known hypersensitivity to the investigational drug.
- Patients with a history of long-term opioid abuse.
- Patients who are unable to communicate effectively.
- Patients with serious comorbid medical conditions, such as uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, or acute asthma exacerbations.
- Patients with a history of epilepsy or a history of manic episodes.
- Pregnant or breastfeeding women.
- Patients with glaucoma.
- Patients with preoperative cognitive dysfunction, bipolar disorder, or other psychiatric disorders, including mental retardation.
- Patients with primary liver cancer in conjunction with malignant tumors of other organs (such as lung, kidney, intestine, etc.), or those with clinical symptoms or imaging findings suggestive of distant metastasis.
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.